Tuore narratiivinen tutkimuskatsaus toteaa, että ateroskleroottiset kardiometabolised sairaudet vaan jylläävät maksimaalisesta lipidien alentamisesta huolimatta ja ehdottaa anti-inflammatorista lääkitystä;
https://link.springer.com/article/10.10 ... 24-00376-3Lainaa:
Key Summary Points
Atherosclerotic cardiovascular events continue to occur despite maximal lipid-lowering therapy (LLT).
High-sensitivity C-reactive protein (hsCRP) has been shown to predict atherosclerotic cardiovascular disease (ASCVD) risk.
hsCRP remains a useful tool to identify an inflammatory residual risk phenotype and may be used to tailor therapy in patients with low-grade chronic inflammation.
To date, repurposed drugs such as colchicine and canakinumab have been shown to significantly reduce the relative risk of major cardiovascular events.
Future trials may indicate that drugs that target interleukin-6, such as ziltivekimab and tocilizumab, could be useful therapies for reducing ASCVD risk.
In the future, combined LLT and anti-inflammatory targeted drug therapies may be used to reduce ASCVD.
Vaan miten olisi anti-inflammatorinen ruokavalio? Terapeuttinen hiilarirajoitus on sellainen.
Kirjaudu sisään
UKK
Etsi
